中国普通外科杂志2016，Vol.25Issue(8)：1186-1192,7.DOI:10.3978/j.issn.1005-6947.2016.08.017
直肠癌患者术后化疗联合CIK免疫治疗的临床疗效
Clinical efficacy of postoperative chemotherapy in combination with CIK immunotherapy in rectal cancer patients
摘要
Abstract
Objective: To investigate the clinical effcacy of postoperative chemotherapy combined with cytokine-induced killer cell (CIK) therapy in rectal cancer patients. <br> Methods: hTe clinical data of 45 rectal cancer patients undergoing postoperative chemotherapy with FOLFOX4 regimen in combination with CIK therapy (CIK plus chemotherapy group) during June 2011 to May 2013 were retrospectively analyzed, and another 45 rectal cancer patients undergoing postoperative chemotherapy alone (chemotherapy alone group) with the same regimen during the same period served as control. hTe quality of life, short-term results, survival rate and adverse reactions between the two groups were compared, and the inlfuential factors for prognosis of rectal cancer patients were also analyzed. <br> Results: In CIK plus chemotherapy group compared with chemotherapy alone group, the improvement rate in quality of life was signiifcantly increased (82.2%vs. 33.3%,P<0.05), the overall response rate had no signiifcant difference (31.1%vs. 22.2%,P>0.05), but the disease control rate was signiifcantly increased (77.8 %vs. 51.1%, P<0.05). hTe 1- and 2-year overall survival rate showed no signiifcant difference (100.0%vs. 97.8%; 93.3%vs. 80%, bothP>0.05), but the 1- and 2-year progression-free survival rate was signiifcantly increased (86.7%vs. 62.2%; 62.2%vs. 40%, bothP<0.05) and the overall incidence of adverse reactions showed no signiifcant difference (46.7%vs. 53.3%,P>0.05). Univariate analysis showed that degree of tumor differentiation, lymph node metastasis, TNM stage and surgical procedure were associated with the prognosis of rectal cancer patients (allP<0.05), and multivariate analysis identified that degree of tumor differentiation and pathological stage were independent prognostic factors (bothP<0.05). <br> Conclusion: Postoperative chemotherapy in combination with CIK immunotherapy can signiifcantly improve the quality of life, increase the overall efficacy, and prolong the progression-free survival rate of rectal cancer patients. The degree of tumor differentiation and pathological stage are independent postoperative prognostic factors for rectal cancer patients.关键词
直肠肿瘤/免疫疗法/细胞因子诱导杀伤细胞/肿瘤联合化疗方案Key words
Rectal Neoplasms/Immunotherapy/Cytokine-Induced Killer Cells/Antineoplastic Combined Chemotherapy Protocols分类
医药卫生引用本文复制引用
刘德宝,孙子雯,李岩,惠丽娜,徐忠法,范开席..直肠癌患者术后化疗联合CIK免疫治疗的临床疗效[J].中国普通外科杂志,2016,25(8):1186-1192,7.基金项目
山东省医药卫生科技发展计划基金资助项目（2013WS0371）。 （）
